Cediranib [clinicaltrials_resource:f3246e36c99ee9337c9bc3ceb8488884]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery [clinicaltrials:NCT00227760]Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer [clinicaltrials:NCT00238394]clinicaltrials:NCT00243061clinicaltrials:NCT00243347clinicaltrials:NCT00244881clinicaltrials:NCT00245063clinicaltrials:NCT00245154clinicaltrials:NCT00264004AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer [clinicaltrials:NCT00275028]Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer [clinicaltrials:NCT00278343]clinicaltrials:NCT00278889clinicaltrials:NCT00303862AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme [clinicaltrials:NCT00305656]clinicaltrials:NCT00306891clinicaltrials:NCT00309946AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia [clinicaltrials:NCT00321581]AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia [clinicaltrials:NCT00321724]AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors [clinicaltrials:NCT00326664]clinicaltrials:NCT00326872clinicaltrials:NCT00384176clinicaltrials:NCT00385203clinicaltrials:NCT00399035clinicaltrials:NCT00410904clinicaltrials:NCT00423332AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer [clinicaltrials:NCT00427973]clinicaltrials:NCT00436956clinicaltrials:NCT00454805Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma [clinicaltrials:NCT00458731]Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer [clinicaltrials:NCT00458978]clinicaltrials:NCT00475150Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours [clinicaltrials:NCT00475956]clinicaltrials:NCT00494221Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases [clinicaltrials:NCT00501605]Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer [clinicaltrials:NCT00502060]Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer [clinicaltrials:NCT00502164]Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML [clinicaltrials:NCT00502385]A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors [clinicaltrials:NCT00502567]Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour [clinicaltrials:NCT00503204]Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors [clinicaltrials:NCT00503412]A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan [clinicaltrials:NCT00503477]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Cediranib [clinicaltrials_resource:f3246e36c99ee9337c9bc3ceb8488884]
Bio2RDF identifier
f3246e36c99ee9337c9bc3ceb8488884
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:f3246e36c99ee9337c9bc3ceb8488884
identifier
clinicaltrials_resource:f3246e36c99ee9337c9bc3ceb8488884
title
Cediranib
@en
type
label
Cediranib [clinicaltrials_resource:f3246e36c99ee9337c9bc3ceb8488884]
@en